Friday, July 24, 2015

Biogen Slashes Outlook on Tecfidera Weakness

Biogen Inc. on Friday slashed its full-year revenue and earnings outlook as sales growth for its key multiple-sclerosis drug continues to weaken.

from WSJ.com: US Business http://ift.tt/1JiLI5y
via IFTTT
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)